Altiratinib
Product Specifications
UNSPSC Description
Altiratinib (DCC-2701) is a multi-targeted kinase inhibitor with IC50s of 2.7, 8, 9.2, 9.3, 0.85, 4.6, 0.83 nM for MET, TIE2, VEGFR2, FLT3, Trk1, Trk2, and Trk3 respectively.
Target Antigen
c-Met/HGFR; FLT3; Trk Receptor; VEGFR
Type
Reference compound
Related Pathways
Neuronal Signaling;Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/Altiratinib.html
Purity
98.05
Solubility
DMSO : 25 mg/mL (ultrasonic)
Smiles
O=C(C1(C(NC2=CC=C(F)C=C2)=O)CC1)NC3=CC(F)=C(OC4=CC(NC(C5CC5)=O)=NC=C4)C=C3F
Molecular Weight
510.46
References & Citations
[1]Smith BD, et al. Altiratinib Inhibits Tumor Growth, Invasion, Angiogenesis, and Microenvironment-Mediated DrugResistance via Balanced Inhibition of MET, TIE2, and VEGFR2. Mol Cancer Ther. 2015 Sep;14(9):2023-34.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-B0791/Altiratinib-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-B0791/Altiratinib-SDS-MedChemExpress.pdf
Clinical Information
Phase 1
CAS Number
1345847-93-9
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
BNC681192-100 100 µL
Anti-Glucose Regulated Protein 94 (GRP94)(HSP90B1/1192), CF568 conjugate
Ask
View Details 
